Study guide

12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles

NBCRNA CRNA Certified Registered Nurse Anesthetist NCE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology

1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems

2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives

3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics

5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies

5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout

6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators

6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging

7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation

7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways

8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety

8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety

9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation

9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication

10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies

11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms

11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)

12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA

12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm

13 Chapter 13: Regional Anesthesia: Neuraxial Blocks

13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma

14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance

14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols

15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice

15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives

16 Chapter 16: Obstetric & Gynecologic Anesthesia

16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient

17 Chapter 17: Pediatric Anesthesia

17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm

18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia

18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction

20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia

20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation

21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology

21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements

22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology

22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices

23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures

23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases

24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control

24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure

25 Chapter 25: Neurosurgical Subspecialty Procedures

25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy

26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia

26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery

27 Chapter 27: Orthopedic & Extremity Anesthesia

27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block

28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy

28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia

29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients

29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient

12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles

Key Takeaways Explain This Topic AI

Balanced general anesthesia combines hypnosis/amnesia, analgesia, and muscle relaxation to capitalize on pharmacologic synergy, whereas Total Intravenous Anesthesia (TIVA) utilizes exclusively IV agents (typically propofol and remifentanil/opioids).

Primary indications for TIVA include history of Malignant Hyperthermia (MH), high PONV risk (Apfel score 3-4), intraoperative neuromonitoring (IONM), laser airway surgery, and neurosurgery where volatile-induced cerebral vasodilation must be prevented.

Volatile halogenated anesthetics >0.5 MAC cause dose-dependent suppression of motor-evoked potentials (MEPs) and somatosensory-evoked potentials (SSEPs), mandating TIVA for reliable spinal cord and cortical pathway monitoring.

Context-sensitive half-time (CSHT) defines the time required for plasma drug concentration to decline by 50% after stopping an infusion; remifentanil exhibits an ultra-short, context-insensitive CSHT of 3-4 minutes due to non-specific blood/tissue esterase metabolism.

Processed electroencephalography (Bispectral Index / BIS) target for general anesthesia is 40-60; values >60 increase the risk of intraoperative awareness with recall, while values <40 indicate deep burst suppression.

Last updated: August 2026

12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles

General anesthesia can be achieved through either balanced anesthesia (the co-administration of inhaled volatile agents, intravenous hypnotics, opioids, and neuromuscular blocking drugs) or Total Intravenous Anesthesia (TIVA) , where hypnotic state, amnesia, and antinociception are sustained exclusively via intravenous infusions. Selecting between these modalities requires understanding pharmacokinetic modeling, context-sensitive half-times, organ clearance pathways, and specialized surgical requirements.

1. The Triad of General Anesthesia & Balanced Anesthetic Rationale

Modern balanced general anesthesia is built upon the classic anesthetic triad:

Hypnosis / Amnesia / Unconsciousness: Provided by volatile agents (Sevoflurane, Desflurane, Isoflurane) or IV hypnotics (Propofol).

Analgesia / Antinociception: Provided by opioids (Fentanyl, Remifentanil, Sufentanil), NMDA antagonists (Ketamine), or α 2 \alpha_2 α 2 ​ -adrenergic agonists (Dexmedetomidine).

Muscle Relaxation / Immobility: Provided by nondepolarizing neuromuscular blocking agents (Rocuronium, Cisatracurium, Vecuronium). [THE BALANCED ANESTHETIC TRIAD]

  • HYPNOSIS
  • (Volatiles, Propofol)
  • / \
  • / \
  • / SYNERGY \
  • / \
  • ANALGESIA ------------ IMMOBILITY
  • (Opioids, Ketamine) (NMBAs: Rocuronium)
  • Pharmacologic Synergy & Side-Effect Blunting

Administering targeted combinations of agents produces supra-additive (synergistic) anesthetic depth. For example, co-administering an opioid infusion (such as remifentanil or fentanyl) reduces the Minimum Alveolar Concentration (MAC) of volatile anesthetics by up to 50 − 70 % 50 - 70\% 50 − 70% . This MAC-sparing effect permits lower volatile concentrations, minimizing dose-dependent myocardial depression, peripheral vasodilation, and prolonged emergence.

2. Clinical Indications for Total Intravenous Anesthesia (TIVA)

Although volatile-based balanced anesthesia is the standard of care for many routine surgical cases, TIVA is specifically indicated in several critical clinical scenarios: +-------------------------------------------------------------------------+

  • | PRIMARY CLINICAL INDICATIONS FOR TIVA |
  • +-----------------------+-------------------------------------------------+
  • | Clinical Scenario | Pathophysiologic & Pharmacologic Rationale |
  • +-----------------------+-------------------------------------------------+
  • | **Malignant | Absolute contraindication to all halogenated |
  • | Hyperthermia (MH)** | volatile gases and succinylcholine; propofol- |
  • | | opioid TIVA is completely non-triggering |
  • | **Intraoperative | Volatile anesthetics (>0.5 MAC) suppress |
  • | Neuromonitoring** | cortical and spinal synaptic transmission, |
  • | (MEPs & SSEPs) | destroying transcranial motor evoked potentials |
  • | **High PONV Risk** | Propofol possesses intrinsic antiemetic actions |
  • | (Apfel Score 3-4) | via D₂ and 5-HT₃ subcortical antagonism |
  • | **Laser Airway / | Eliminates volatile gas pollution and reduces |
  • | Shared Airway** | airway fire risk during tubeless / jet surgery |
  • | **Neurosurgery / | Volatiles cause cerebral vasodilation at >0.6 |
  • | Elevated ICP** | MAC; propofol couples CBF reduction with CMRO₂ |
  • | | reduction, maintaining intracranial compliance |
  • | **Mitochondrial | Prevents volatile-induced uncoupling of |
  • | Myopathies** | oxidative phosphorylation |
  • +-----------------------+-------------------------------------------------+
  • Intraoperative Neuromonitoring (IONM) Specifics

Motor Evoked Potentials (MEPs): Transcranial electrical stimulation of the motor cortex generates action potentials traversing the corticospinal tract to peripheral muscle recording sites. The anterior horn α \alpha α -motor neuron synapses are exceptionally sensitive to volatile anesthetics. Inhaled agents at > 0.5 MAC >0.5 \text{ MAC} > 0.5 MAC cause profound, dose-dependent reductions in MEP amplitude ( > 50 % >50\% > 50% ) and prolongation of latency. NMBAs must also be avoided or tightly controlled.

Somatosensory Evoked Potentials (SSEPs): Ascend through the dorsal column-medial lemniscal pathway. Volatile agents reduce SSEP amplitude and increase latency.

Standard IONM TIVA Regimen: Propofol ( 100 − 150 mcg/kg/min 100 - 150 \text{ mcg/kg/min} 100 − 150 mcg/kg/min ) + Remifentanil ( 0.1 − 0.3 mcg/kg/min 0.1 - 0.3 \text{ mcg/kg/min} 0.1 − 0.3 mcg/kg/min ) provides deep surgical anesthesia while leaving MEP and SSEP signal quality pristine.

3. Pharmacokinetics of Continuous Infusions: Three-Compartment Modeling

Intravenous anesthetic distribution is best described by a three-compartment mammillary pharmacokinetic model :

Central Compartment ( V 1 V_1 V 1 ​ ): Rapidly equilibrating blood volume and highly perfused vessel-rich group (brain, heart, liver, kidneys; represents ≈ 10 % \approx 10\% ≈ 10% of body mass, receives 75 % 75\% 75% of cardiac output).

Rapid Peripheral Compartment ( V 2 V_2 V 2 ​ ): Muscle and skin.

Slow Peripheral Compartment ( V 3 V_3 V 3 ​ ): Adipose tissue and poorly perfused connective tissues. [THREE-COMPARTMENT MAMMILLARY MODEL]

  • Rapid Peripheral
  • Compartment (V₂)
  • ^ |
  • k₁₂ | | k₂₁
  • | v
  • [IV Infusion / Dose] --> CENTRAL COMPARTMENT (V₁) --> Elimination (k₁₀)
  • | ^
  • k₁₃ | | k₃₁
  • v |
  • Slow Peripheral
  • Compartment (V₃)
  • Micro-Rate Constants & Clearance Kinetics

k 10 k_{10} k 10 ​ : Rate constant of irreversible metabolic drug elimination from the central compartment ( V 1 V_1 V 1 ​ ).

k 12 , k 21 k_{12}, k_{21} k 12 ​ , k 21 ​ : Distribution rate constants between central and rapid peripheral compartments.

k 13 , k 31 k_{13}, k_{31} k 13 ​ , k 31 ​ : Distribution rate constants between central and slow peripheral compartments.

Following an IV bolus, drug concentration in V 1 V_1 V 1 ​ drops precipitously primarily due to rapid redistribution into V 2 V_2 V 2 ​ and V 3 V_3 V 3 ​ (the distribution α \alpha α -phase), rather than immediate hepatic elimination (the elimination β \beta β -phase).

4. Context-Sensitive Half-Time (CSHT) & Effect-Site Equilibration ( k e 0 k_{e0} k e 0 ​ )

The elimination half-life ( t 1 / 2 β t_{1/2\beta} t 1/2 β ​ ) is an unreliable predictor of recovery following continuous intravenous infusions because it ignores the extensive accumulation of drug in peripheral storage compartments ( V 2 , V 3 V_2, V_3 V 2 ​ , V 3 ​ ).

Defining Context-Sensitive Half-Time (CSHT)

Context-Sensitive Half-Time (CSHT) is defined as the time required for the central compartment (plasma) drug concentration to decrease by 50 % 50\% 50% after the termination of a continuous infusion of a specified duration (the "context"). [CONTEXT-SENSITIVE HALF-TIME PROFILES]

  • CSHT (Minutes)
  • 300 |
  • | /--- FENTANYL (Steep rise)
  • 240 | /
  • | /
  • 180 | /
  • | /
  • 120 | / /---- SUFENTANIL
  • | / /
  • 60 | /-----------------/---/------ MIDAZOLAM
  • | /----------------------------- PROPOFOL (~20-30 min plateau)
  • 0 +---------------+---------------+---------------+-----> Infusion Duration
  • 0 2 4 8 (Hours)

............................................... REMIFENTANIL (Flat ~3-4 min) +-------------------------------------------------------------------------+

  • | DRUG CSHT COMPARISON SUMMARY |
  • +------------------+-----------------------------+------------------------+
  • | Anesthetic Drug | CSHT Profile After 4-8 hr | Primary Mechanism |
  • +------------------+-----------------------------+------------------------+
  • | **Remifentanil** | **Constant: 3 - 4 minutes** | Rapid hydrolysis by |
  • | | (Context-insensitive) | non-specific blood and |
  • | | | tissue esterases |
  • | **Propofol** | **Short: 20 - 30 minutes** | High metabolic clear- |
  • | | (Flattens due to clearance) | ance + redistribution |
  • | **Sufentanil** | Intermediate (~30-40 min) | High clearance, slow V₃|
  • | **Fentanyl** | **Prolonged: > 200 minutes**| Massive accumulation in|
  • | | (Steep exponential rise) | fat with slow return |
  • | **Midazolam** | Prolonged (> 100 minutes) | Hepatic saturation and |
  • | | | active metabolites |
  • +------------------+-----------------------------+------------------------+
  • Effect-Site Equilibration ( k e 0 k_{e0} k e 0 ​ ) & Hysteresis

The biophase (effect compartment) represents the actual site of drug action within the central nervous system. Because drug must cross the blood-brain barrier, a temporal delay ( hysteresis ) occurs between peak plasma concentration ( C p C_p C p ​ ) and peak clinical effect ( C e C_e C e ​ ).

k e 0 k_{e0} k e 0 ​ : The first-order rate constant describing drug exit from the effect compartment.

t 1 / 2 k e 0 t_{1/2} k_{e0} t 1/2 ​ k e 0 ​ (Equilibration Half-Time): Time required to achieve 50 % 50\% 50% equilibration between plasma and effect site ( t 1 / 2 k e 0 = ln ⁡ 2 k e 0 t_{1/2} k_{e0} = \frac{\ln 2}{k_{e0}} t 1/2 ​ k e 0 ​ = k e 0 ​ l n 2 ​ ).

Propofol: t 1 / 2 k e 0 ≈ 2 − 3 minutes t_{1/2} k_{e0} \approx 2 - 3 \text{ minutes} t 1/2 ​ k e 0 ​ ≈ 2 − 3 minutes (peak clinical hypnosis at ≈ 2 minutes \approx 2 \text{ minutes} ≈ 2 minutes post-bolus).

Remifentanil: t 1 / 2 k e 0 ≈ 1 − 1.5 minutes t_{1/2} k_{e0} \approx 1 - 1.5 \text{ minutes} t 1/2 ​ k e 0 ​ ≈ 1 − 1.5 minutes (nearly instantaneous effect-site tracking).

Fentanyl: t 1 / 2 k e 0 ≈ 4 − 6 minutes t_{1/2} k_{e0} \approx 4 - 6 \text{ minutes} t 1/2 ​ k e 0 ​ ≈ 4 − 6 minutes .

5. Target-Controlled Infusion (TCI) Principles & Models

Target-Controlled Infusion (TCI) systems use computerized microprocessor-driven syringe pumps programmed with pharmacokinetic/pharmacodynamic population models to maintain a user-selected target drug concentration in either plasma ( C p C_p C p ​ ) or the effect site ( C e C_e C e ​ ). +-------------------------------------------------------------------------+

  • | COMMON PROPOFOL TCI PHARMACOKINETIC MODELS |
  • +--------------------+-------------------------+--------------------------+
  • | Model Feature | Marsh Model | Schnider Model |
  • +--------------------+-------------------------+--------------------------+
  • | **Patient Inputs** | Weight only | Age, Height, Weight, |
  • | | | Lean Body Mass (LBM) |
  • | **Central Volume** | Proportional to weight | Fixed small V₁ (4.27 L) |
  • | ($V_1$) | ($V_1 = 0.228 \text{ L/kg}$) | |
  • | **Clearance** | Weight-proportional | Decreases with age |
  • | **Optimal Use** | General adult population| Elderly and obese |
  • | | | patients (avoids overdose|
  • +--------------------+-------------------------+--------------------------+

Minto Model for Remifentanil: Incorporates age, height, weight, and lean body mass. Accounts for reduced central clearance and smaller distribution volumes in elderly patients.

6. Processed EEG & Depth of Anesthesia Monitoring

Processed electroencephalography (e.g., Bispectral Index / BIS, SedLine) translates raw frontal cortical electrical activity into a dimensionless index ranging from 0 to 100 to assess hypnotic depth and prevent intraoperative awareness with recall. +-------------------------------------------------------------------------+

  • | BISPECTRAL INDEX (BIS) SCALE |
  • +------------------+------------------------------------------------------+
  • | BIS Index Value | Clinical / Electroencephalographic State |
  • +------------------+------------------------------------------------------+
  • | **90 - 100** | Fully awake, alert, responsive; high-frequency beta |
  • | **60 - 80** | Moderate sedation; response to loud verbal commands |
  • | **40 - 60** | **General Anesthesia Target Range** |
  • | | (Low awareness probability; adequate cortical sup.) |
  • | **20 - 40** | Deep hypnotic state; burst suppression pattern on EEG|
  • | **0 - 20** | Profound burst suppression / isoelectric progression |
  • | **0** | Completely flatline (isoelectric) EEG |

+------------------+------------------------------------------------------+ [RAW EEG WAVE PROGRESSION TO BURST SUPPRESSION]

1. Awake (Beta: >13 Hz) wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww

2. Light Anesthesia (Alpha: 8-12 Hz) ~\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/~

3. Surgical Plane (Delta: 0.5-4 Hz) ~~/\____/\____/\____/\____/\____~ governance

  • 4. Deep Anesthesia (Burst Suppression) --/\/\/\/\/-------/\/\/\/\/------
  • (Burst) (Suppression) (Burst)
  • Clinical Traps & Confounding Factors in Processed EEG

Ketamine & Nitrous Oxide Paradox: Ketamine and N 2 O N_2O N 2 ​ O stimulate high-frequency cortical beta oscillations, producing falsely elevated BIS numbers (e.g., 70-80) despite profound surgical anesthesia and patient unresponsiveness.

Electrosurgical Interference: High-frequency electrocautery currents generate radiofrequency artifacts that artificially distort BIS calculations.

Hypothermia & Hypoglycemia: Lower cerebral metabolic rate and slow EEG background frequencies, falsely driving the BIS score down toward burst suppression.

Awareness Risk Populations: Patients undergoing emergency trauma surgery, urgent Cesarean section, cardiac surgery with cardiopulmonary bypass, and those with chronic substance or opioid dependence.

Loading diagram... TIVA vs Balanced Anesthesia Clinical Decision Matrix